Recruiting

Testing a new injectable treatment for severe skin inflammation diseases

Plain-English translation of NCT06524635 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This trial is testing an experimental medication called in adults with two serious chronic skin conditions: hidradenitis suppurativa (painful, recurring boils and abscesses) or atopic dermatitis (severe eczema). Researchers want to understand how this medication works in the body and whether it can help reduce the inflammation and symptoms these diseases cause.

Both hidradenitis suppurativa and atopic dermatitis are painful, long-lasting skin conditions that significantly impact quality of life. Some patients don't improve with current treatments, so researchers are developing this medication as a potential new option for people who need better control of their symptoms.

Do you qualify?

You likely qualify if…

you have been diagnosed with moderate-to-severe hidradenitis suppurativa for at least 6 months, or moderate-to-severe atopic dermatitis for at least 1 year
you are either new to biologic (injectable) medications for your skin condition, or you've tried existing biologic treatments without adequate improvement
you are an adult and able to attend regular clinic visits over several months
you do not have an active skin infection requiring antibiotics or antifungal medication

You likely don't qualify if…

you have had any cancer diagnosis in the past 5 years (except for non-melanoma skin cancer that was successfully treated)
you currently have active skin infections requiring systemic treatment
you have other active skin diseases that could interfere with assessing your hidradenitis suppurativa or atopic dermatitis
you have been diagnosed with active malignancy

What participation looks like

You will receive subcutaneous injections (shots under the skin) of the medication at a clinic over approximately 15–16 weeks, followed by a 70-day follow-up period. You'll attend regular clinic visits that may include blood tests and skin assessments to measure how the medication affects your condition. If you have hidradenitis suppurativa and see improvement, you may have the option to continue receiving the medication for up to an additional 2.5+ years in an extension program.

Testing a new injectable treatment for severe skin inflammation diseases

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)